Alopexx seeks $11M IPO to advance ex-Sanofi infectious disease drug
Alopexx is forging ahead with long-gestating plans to go public, updating IPO paperwork to fund trials of candidates including an infectious disease antibody that was once the focus of a $375 million deal with Sanofi.
Alopexx is forging ahead with long-gestating plans to go public, updating IPO paperwork to fund trials of candidates including an infectious disease antibody that was once the focus of a $375 million deal with Sanofi.
